Hansa Biopharma AB - ESG Rating & Company Profile powered by AI
The webpage displays a zero-cost Environmental, Social and Governance report for Hansa Biopharma AB. This analysis of Hansa Biopharma AB incorporates information from across the internet as well as from public filings by Hansa Biopharma AB. This assessment of Hansa Biopharma AB is assembled by All Street Sevva using advanced artificial intelligence.
Hansa Biopharma AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.6; made up of an environmental score of 8.0, social score of 8.0 and governance score of 6.7.
7.6
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 187 | Richter Gedeon Vegyeszeti Gyar Nyrt | 7.7 | High |
| 187 | Vitrolife AB | 7.7 | High |
| 209 | Hansa Biopharma AB | 7.6 | High |
| 209 | Actinogen Medical Ltd | 7.6 | High |
| 209 | Bajaj Healthcare Ltd | 7.6 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Hansa Biopharma AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Hansa Biopharma AB disclose current and historical energy intensity?
Sign up for free to unlockDoes Hansa Biopharma AB report the average age of the workforce?
Sign up for free to unlockDoes Hansa Biopharma AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Hansa Biopharma AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes Hansa Biopharma AB disclose cybersecurity risks?
Sign up for free to unlockDoes Hansa Biopharma AB offer flexible work?
Sign up for free to unlockDoes Hansa Biopharma AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Hansa Biopharma AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Hansa Biopharma AB conduct supply chain audits?
Sign up for free to unlockDoes Hansa Biopharma AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Hansa Biopharma AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes Hansa Biopharma AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes Hansa Biopharma AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Hansa Biopharma AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Hansa Biopharma AB disclose water use targets?
Sign up for free to unlockDoes Hansa Biopharma AB have careers partnerships with academic institutions?
Sign up for free to unlockDid Hansa Biopharma AB have a product recall in the last two years?
Sign up for free to unlockDoes Hansa Biopharma AB disclose incidents of discrimination?
Sign up for free to unlockDoes Hansa Biopharma AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Hansa Biopharma AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Hansa Biopharma AB disclose parental leave metrics?
Sign up for free to unlockDoes Hansa Biopharma AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Hansa Biopharma AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Hansa Biopharma AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes Hansa Biopharma AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Hansa Biopharma AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Hansa Biopharma AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Hansa Biopharma AB involved in embryonic stem cell research?
Sign up for free to unlockDoes Hansa Biopharma AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Hansa Biopharma AB disclose its waste policy?
Sign up for free to unlockDoes Hansa Biopharma AB report according to TCFD requirements?
Sign up for free to unlockDoes Hansa Biopharma AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Hansa Biopharma AB disclose energy use targets?
Sign up for free to unlockDoes Hansa Biopharma AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Hansa Biopharma AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Hansa Biopharma AB
These potential risks are based on the size, segment and geographies of the company.
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.